Why the UK medicine supply chain is dangerously exposed to global shocks

**Lead**

The United Kingdom’s medicine supply chain remains critically exposed to global shocks, according to a growing body of evidence from regulators, industry bodies, and parliamentary inquiries. Despite lessons learned from the COVID-19 pandemic, the country still imports the vast majority of its active pharmaceutical ingredients (APIs) and finished medicines from a handful of overseas suppliers, leaving the National Health Service (NHS) and patients vulnerable to disruptions caused by pandemics, trade disputes, extreme weather, and geopolitical instability.

**Context**

The UK’s pharmaceutical supply chain is a complex web of manufacturers, wholesalers, and logistics providers that has evolved over decades to prioritise cost efficiency over resilience. The country now imports roughly 70 percent of its medicines, with a significant share coming from the European Union, India, and China. Many of the APIs used in UK-manufactured drugs are sourced from a small number of factories in China and India, creating single-point-of-failure risks. The COVID-19 pandemic exposed these vulnerabilities when lockdowns in India and shipping disruptions led to shortages of critical drugs such as paracetamol, antibiotics, and anaesthetics.

Brexit has compounded the problem. Since the UK left the EU single market and customs union in 2021, new customs checks, regulatory divergence, and increased paperwork have slowed the flow of medicines from Europe. The Department of Health and Social Care has acknowledged that the new trade barriers have made it harder to maintain buffer stocks. The Medicines and Healthcare products Regulatory Agency (MHRA) has also warned that the UK’s departure from the European Medicines Agency (EMA) has reduced the speed of regulatory approvals for new drugs, further straining supply.

Just-in-time inventory practices, adopted by NHS trusts and wholesalers to cut costs, mean that stockpiles are often minimal. A 2023 report by the House of Commons Health and Social Care Committee found that the NHS holds only a few weeks’ worth of many essential medicines, far below the three-month target recommended by the World Health Organization. The report also highlighted that the UK has lost much of its domestic manufacturing capacity over the past two decades, with many factories closing or moving abroad due to cheaper labour and less stringent environmental regulations.

**Analise**

The implications of this exposure are severe. A single disruption—such as a factory fire in China, a trade embargo, or a new pandemic—could trigger widespread shortages of medicines that are not easily substitutable. For example, the UK relies on a single supplier for certain anaesthetic agents and chemotherapy drugs. If that supplier fails, patients could face delayed surgeries or interrupted cancer treatment. The recent energy crisis in Europe, driven by the war in Ukraine, has already pushed up production costs for several API manufacturers, leading to price hikes and reduced output.

Moreover, the UK’s regulatory independence post-Brexit has not yet translated into a more resilient supply chain. The government’s own “Life Sciences Vision” published in 2021 promised to boost domestic manufacturing and stockpiling, but progress has been slow. The Treasury has been reluctant to fund large-scale strategic reserves, and industry leaders have complained about a lack of coordination between the Department of Health, the Department for Business and Trade, and the Treasury. Without a coherent national strategy, the UK remains at the mercy of global events.

Another layer of risk comes from the growing concentration of API production in China and India. Geopolitical tensions between the West and China could lead to export controls or sanctions that cut off supplies. The UK’s limited ability to produce its own penicillin, paracetamol, or insulin means that any such disruption would be felt immediately in hospitals and pharmacies. The situation is particularly dangerous for generic medicines, which account for the majority of NHS prescriptions but are produced on thin margins, leaving little incentive for manufacturers to hold extra stock.

**Fontes**

- House of Commons Health and Social Care Committee, “The Safety of Medicines and Medical Devices” (2023). - Department of Health and Social Care, “UK Medicines Supply Chain Resilience” (2022). - Medicines and Healthcare products Regulatory Agency (MHRA), “Supply Chain Vulnerability Assessment” (2023). - British Generic Manufacturers Association (BGMA), “Securing the UK’s Medicine Supply” (2024). - NHS England, “Medicine Shortages Data” (2023). - World Health Organization, “Essential Medicines Stockpiling Guidelines” (2021).